Where is the live CopyMark page for USPTO serial 79147352?

The live record is at https://getcopymark.com/trademark/79147352. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns BACHEM PIONEERING PARTNER FOR PEPTIDES?

According to the public USPTO record for serial number 79147352, the listed owner(s) include: Bachem Holding AG, Bachem Holding AG, Bachem Holding AG.

What is USPTO serial number 79147352?

Serial number 79147352 is the USPTO application identifier for the mark BACHEM PIONEERING PARTNER FOR PEPTIDES. It is used to track examination, publication, and registration of this trademark.

What is the current status of BACHEM PIONEERING PARTNER FOR PEPTIDES?

BACHEM PIONEERING PARTNER FOR PEPTIDES (79147352) currently shows USPTO status code 404 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Which trademark classes cover BACHEM PIONEERING PARTNER FOR PEPTIDES?

The public record lists International Classes: 001, 005. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: BACHEM PIONEERING PARTNER FOR PEPTIDES Serial# 79147352 | status 404; last event DENA | Trademark Info & Attorney Guidance

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BACHEM PIONEERING PARTNER FOR PEPTIDES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Alex R Sluzas

Alex R Sluzas Paul and Paul1717 Arch StreetSuite 3740Philadelphia, PA 19103

Goods and services

Class	Description	Status	First use
001	Chemicals for use in industry and science, namely, amino acids, peptides, reagents for peptide synthesis, amino acid derivatives, cytokines, enzyme inhibitors, enzyme substrates, growth factors, peptide substrates, all for use as scientific and laboratory research reagents in the field of medicine and molecular biology; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; chemical products used for preserving foodstuffs	SECTION 71 - CANCELLED	—
005	Pharmaceutical and veterinary products, namely, pharmaceutical preparations for use in the treatment of bleeding, premature labor, pulmonary hypertension, erectile disfunction, coronary syndromes, prostate cancer, endometriosis, central precocious puberty, uterine myoma, osteoporosis, hypercalcernia, Paget's disease, reflex sympathetic dystrophy, nocturnal enureses, central diabetes insipidus, polyuria, polydipsia, hemophilia A, von Willebrand disease, unstable angina, myocardial infarction, hypoglycemia, ovarian follicular cysts, cryptochism, breast cancer, growth hormone deficiency, acromegaly, carcinoid syndrome, thyrotrophic adenomas, diabetes II, VIPosmas, ulcer bleeding, hemorrhagic gastritis, postoperative pancreatic and duodenal fistulae, variceal hemorrhage, neurological diseases, rheumatic diseases, skin diseases, diseases of the intestinal tract, cancer, conjunctivitis, glaucoma, ocular hypertension, Parkinson's disease, transfusion-induced hemosiderosis, candidasis, dermatophytosis, pityriasis, congenital homocystinuria, hyperammonaemia, hepatic encephalopathy, ischemic heart disease, chorioretinal vascular disorders, hypertension, endema, insomnia, bipolar disorder, and schizophrenia; pharmaceutical preparations for use in the diagnosis of gastrinoma; veterinary preparations for use in the induction of ovulation in estrous mares, and reproduction control in dogs and cats; pharmaceutical preparations for use in the diagnosis of Cushing's syndrome, hypothalamic-pituitary-gonadal axis function, growth hormone deficiency, pancreatic exocrine dysfunction, gastrinoma, and adrenocortical insufficiency; dietetic food and substances for medical or veterinary use, namely, taste-modulating food additives in the nature of peptides for medical use, appetite suppressors for medical use; food supplements for humans and animals; fungicides; herbicides	SECTION 71 - CANCELLED	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Nov 1, 2024	DENA	NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED	—
Nov 1, 2024	DETH	DEATH OF INTERNATIONAL REGISTRATION	—
Oct 24, 2022	INNT	TOTAL INVALIDATION PROCESSED BY THE IB	—
Sep 22, 2022	INTS	TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB	—
Sep 22, 2022	INPC	INVALIDATION PROCESSED	—
Aug 10, 2022	INTR	TOTAL INVALIDATION OF REG EXT PROTECTION CREATED	—
Dec 10, 2021	C71T	CANCELLED SECTION 71	—
May 26, 2020	REM3	COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED	—
Feb 1, 2019	NREP	NEW REPRESENTATIVE AT IB RECEIVED	—
Oct 30, 2015	FINO	FINAL DECISION TRANSACTION PROCESSED BY IB	—
Sep 24, 2015	FICS	FINAL DISPOSITION NOTICE SENT TO IB	—
Sep 24, 2015	FIMP	FINAL DISPOSITION PROCESSED	—
Aug 26, 2015	FICR	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB	—
May 26, 2015	R.PR	REGISTERED-PRINCIPAL REGISTER	Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 10, 2015	NPUB	OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	—
Mar 10, 2015	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 6, 2015	GPNX	NOTIFICATION PROCESSED BY IB	—
Feb 18, 2015	OPNS	NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB	—
Feb 18, 2015	OP2R	NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB	—
Feb 18, 2015	NONP	NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	—
Jan 30, 2015	PREV	LAW OFFICE PUBLICATION REVIEW COMPLETED	—
Jan 29, 2015	ALIE	ASSIGNED TO LIE	—
Jan 9, 2015	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Jan 9, 2015	XAEC	EXAMINER'S AMENDMENT ENTERED	—
Jan 9, 2015	GNEN	NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED	—
Jan 9, 2015	GNEA	EXAMINERS AMENDMENT E-MAILED	—
Jan 9, 2015	CNEA	EXAMINERS AMENDMENT -WRITTEN	—
Jan 8, 2015	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
Jan 8, 2015	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Jan 8, 2015	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 8, 2014	RFNT	REFUSAL PROCESSED BY IB	—
Jul 23, 2014	RFCS	NON-FINAL ACTION MAILED - REFUSAL SENT TO IB	—
Jul 23, 2014	RFRR	REFUSAL PROCESSED BY MPU	—
Jul 18, 2014	RFCR	NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW	—
Jul 17, 2014	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 17, 2014	DOCK	ASSIGNED TO EXAMINER	—
Jun 3, 2014	MAFR	APPLICATION FILING RECEIPT MAILED	—
May 30, 2014	NWOS	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	—
May 29, 2014	REPR	SN ASSIGNED FOR SECT 66A APPL FROM IB	—

BACHEM PIONEERING PARTNER FOR PEPTIDES